{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T07:04:31Z","timestamp":1792134271957,"version":"4.4.0"},"reference-count":17,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Magnetic resonance imaging (MRI) has been proposed to enhance the benefit-to-harm ratio of prostate cancer screening, but data on repeated screening outcomes are lacking.<\/jats:p><\/jats:sec>Objective<\/jats:title>To describe outcomes of prostate-specific antigen (PSA)\u2013based screening with MRI and prostate biopsies at repeat screening.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This secondary analysis examined the population-based, screen-by-invitation STHLM3-MRI randomized clinical trial, which recruited Swedish men aged 50 to 74 years. Men were eligible for repeat screening at 2 to 3 years if they had PSA levels of 1.5 ng\/mL or greater at trial inclusion, were randomized to the MRI-targeted group (including screening using biomarkers and MRI), and were not diagnosed with prostate cancer after the first screening round. Repeat screening was performed between November 10, 2021, and February 20, 2023. Data analysis was performed between May and August 2023.<\/jats:p><\/jats:sec>Intervention<\/jats:title>Participants underwent blood sampling, including PSA testing. A biparametric MRI scan was performed if PSA levels were 3 ng\/mL or greater, and men with lesions with a Prostate Imaging\u2013Reporting and Data System (PI-RADS) score of 3 or greater were referred for targeted and systematic biopsies.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The primary outcome was clinically significant prostate cancer (Gleason score of \u22653\u2009+\u20094). Secondary outcomes included the proportion of men with clinically insignificant cancer (Gleason score of 6), the number of elevated PSA tests, MRI scans, and biopsy procedures.<\/jats:p><\/jats:sec>Results<\/jats:title>Of 7609 men from the first screening round, 2078 (27.3%) were eligible for and were invited for rescreening. Among the invitees, 1500 (72.2%) participated. Their median age was 67 (IQR, 61-72) years. Of 1094 men with PSA levels between 1.5 and 2.9 ng\/mL in the first screening round, 326 (29.8%) had levels of 3 ng\/mL or greater in the second round. Overall, 667 men (44.5%) had PSA levels of 3 ng\/mL or greater: 617 underwent MRI (92.5%), revealing 51 (7.6%) with equivocal lesions (PI-RADS score of 3) and 33 (4.9%) with suspicious lesions (PI-RADS score of \u22654). Only 10 of 383 men (2.6%) with a prior negative MRI result had a lesion with a PI-RADS score of 4 or greater. Among the 1500 rescreened men, 48 (3.2%) had a Gleason score of 3\u2009+\u20094 or greater, including 19 (1.3%) with a score of 4\u2009+\u20093 or greater and 11 (0.7%) with a score of 6.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this secondary analysis of the STHLM3-MRI randomized clinical trial, cancer detection during the second screening round in biennial PSA and MRI-based prostate cancer screening was limited, and the detection of low-grade tumors remained low. A substantial proportion of men exhibited elevated PSA levels during rescreening, and a considerable portion of MRI scans performed lacked lesions suggestive of cancer. Future studies should explore strategies to reduce MRI-related resource use.<\/jats:p><\/jats:sec>Trial Registration<\/jats:title>ClinicalTrials.gov Identifier: NCT03377881<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2023.54577","type":"journal-article","created":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T16:03:09Z","timestamp":1707321789000},"page":"e2354577","source":"Crossref","is-referenced-by-count":34,"title":["Repeated Prostate Cancer Screening Using Prostate-Specific Antigen Testing and Magnetic Resonance Imaging"],"prefix":"10.1001","volume":"7","author":[{"given":"Tobias","family":"Nordstr\u00f6m","sequence":"first","affiliation":[{"name":"Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden"},{"name":"Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus","family":"Annerstedt","sequence":"additional","affiliation":[{"name":"C-Medical Urology Odenplan, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Glaessgen","sequence":"additional","affiliation":[{"name":"Department of Clinical Pathology and Cytology, Unilabs, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Carlsson","sequence":"additional","affiliation":[{"name":"Department of Urology, Karolinska University Hospital Solna, Stockholm, Sweden"},{"name":"Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Clements","sequence":"additional","affiliation":[{"name":"Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Abbadi","sequence":"additional","affiliation":[{"name":"Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Gr\u00f6nberg","sequence":"additional","affiliation":[{"name":"Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik","family":"J\u00e4derling","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden"},{"name":"Department of Diagnostic Radiology, Karolinska University Hospital, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Eklund","sequence":"additional","affiliation":[{"name":"Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Discacciati","sequence":"additional","affiliation":[{"name":"Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2024,2,7]]},"reference":[{"issue":"9959","key":"zoi231596r1","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1016\/S0140-6736(14)60525-0","article-title":"Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up.","volume":"384","author":"Schr\u00f6der","year":"2014","journal-title":"Lancet"},{"issue":"23","key":"zoi231596r2","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1056\/NEJMoa2209454","article-title":"Prostate cancer screening with PSA and MRI followed by targeted biopsy only.","volume":"387","author":"Hugosson","year":"2022","journal-title":"N Engl J Med"},{"issue":"10","key":"zoi231596r3","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1056\/NEJMoa2100852","article-title":"MRI-targeted or standard biopsy in prostate cancer screening.","volume":"385","author":"Eklund","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"zoi231596r4","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","article-title":"EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer-2020 update. Part 1: screening, diagnosis, and local treatment with curative intent.","volume":"79","author":"Mottet","year":"2021","journal-title":"Eur Urol"},{"issue":"3","key":"zoi231596r5","doi-asserted-by":"publisher","first-page":"236","DOI":"10.6004\/jnccn.2023.0014","article-title":"NCCN Guidelines\u00ae insights: prostate cancer early detection, version 1.2023.","volume":"21","author":"Moses","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"issue":"6","key":"zoi231596r6","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1016\/j.euf.2022.06.008","article-title":"Designing and implementing a population-based organised prostate cancer testing programme.","volume":"8","author":"Alterbeck","year":"2022","journal-title":"Eur Urol Focus"},{"issue":"9","key":"zoi231596r8","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1001\/jama.2018.0154","article-title":"Effect of a low-intensity PSA-based screening intervention on prostate cancer mortality: the CAP randomized clinical trial.","volume":"319","author":"Martin","year":"2018","journal-title":"JAMA"},{"issue":"1","key":"zoi231596r9","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.euo.2021.09.001","article-title":"Prostate cancer screening with magnetic resonance imaging: results from the second round of the G\u00f6teborg Prostate Cancer Screening 2 Trial.","volume":"5","author":"Wallstr\u00f6m","year":"2022","journal-title":"Eur Urol Oncol"},{"issue":"4","key":"zoi231596r10","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.eururo.2013.05.030","article-title":"Screening for prostate cancer: results of the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer.","volume":"64","author":"Roobol","year":"2013","journal-title":"Eur Urol"},{"issue":"9","key":"zoi231596r11","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/S1470-2045(21)00348-X","article-title":"Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial.","volume":"22","author":"Nordstr\u00f6m","year":"2021","journal-title":"Lancet Oncol"},{"issue":"2","key":"zoi231596r12","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1097\/PAS.0000000000000530","article-title":"The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: definition of grading patterns and proposal for a new grading system.","volume":"40","author":"Epstein","year":"2016","journal-title":"Am J Surg Pathol"},{"issue":"19","key":"zoi231596r13","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1056\/NEJMoa1801993","article-title":"MRI-targeted or standard biopsy for prostate-cancer diagnosis.","volume":"378","author":"Kasivisvanathan","year":"2018","journal-title":"N Engl J Med"},{"issue":"16","key":"zoi231596r14","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1016\/S1470-2045(15)00361-7","article-title":"Prostate cancer screening in men aged 50-69 years (STHLM3): a prospective population-based diagnostic study.","volume":"16","author":"Gr\u00f6nberg","year":"2015","journal-title":"Lancet Oncol"},{"issue":"8","key":"zoi231596r15","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/S1470-2045(10)70146-7","article-title":"Mortality results from the G\u00f6teborg randomised population-based prostate-cancer screening trial.","volume":"11","author":"Hugosson","year":"2010","journal-title":"Lancet Oncol"},{"issue":"17","key":"zoi231596r16","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJMoa2214122","article-title":"Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer.","volume":"388","author":"Hamdy","year":"2023","journal-title":"N Engl J Med"},{"issue":"3","key":"zoi231596r17","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.eururo.2020.03.048","article-title":"Negative predictive value of multiparametric magnetic resonance imaging in the detection of clinically significant prostate cancer in the prostate imaging reporting and data system era: a systematic review and meta-analysis.","volume":"78","author":"Sathianathen","year":"2020","journal-title":"Eur Urol"},{"key":"zoi231596r7","unstructured":"European Commission Directorate-General for Health and Food Safety. Proposal for a Council Recommendation (CR) on Strengthening prevention through early detection: a new approach on cancer screening replacing CR 2003\/878\/EC. September 20, 2022. Accessed August 14, 2023. https:\/\/health.ec.europa.eu\/system\/files\/2022-09\/com_2022-474_act_en.pdf"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2814623\/nordstrm_2024_oi_231596_1706304758.65294.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T16:03:16Z","timestamp":1707321796000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2814623"}},"subtitle":["A Secondary Analysis of the STHLM3-MRI Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2024,2,7]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2,5]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.54577","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,7]]}}}